Memgen Announces New Clinical Data on MEM-288 in Advanced/Metastatic NSCLC at ASCO 2023 Annual Meeting
Memgen, Inc., a clinical-stage biotechnology company today announced updated clinical data from its first-in-human study of MEM-288, an oncolytic viral therapy, in patients with advanced/metastatic refractory non-small cell lung cancer. Dr. Andreas Saltos, the lead study investigator at Moffitt Cancer Center, presented the poster presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago.
